Navigation Links
Study of Cell Therapeutics' Tosedostat for Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Now Enrolling
Date:6/17/2012

SEATTLE, June 18, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) today announced that the University of Washington ("UW") has begun enrolling patients in a randomized phase II study testing the combination of tosedostat with either cytarabine or decitabine for elderly patients with newly-diagnosed acute myeloid leukemia ("AML") or high-risk myelodysplastic syndrome ("MDS"). 

Drs. John Pagel and Elihu Estey, from the University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, are leading the study.

"This is the first study to examine the effects of tosedostat in combination with either cytarabine or decitabine as a first-line therapy.  The study will evaluate how well patients tolerate these combinations, and their effectiveness.  Given that there have been no major advances in treatment of elderly patients with AML, and the results of a previous study of tosedostat by itself in relapsed or refractory patients with AML or MDS showed promising anti-leukemic effects and acceptable tolerability, we are hopeful that this study will demonstrate that tosedostat increases the limited efficacy of these commonly used anti-leukemic agents," Dr. Estey said.

The study's primary objectives are to determine the four-month survival and complete response ("CR") rates of tosedostat in combination with either cytarabine or decitabine in untreated AML or high-risk MDS. The study's secondary objectives are to assess the safety and tolerability of tosedostat in combination with either cytarabine or decitabine, to determine the treatment-related mortality rate (defined as death within the first 30 days of beginning treatment), and to estimate the rates of disease-free survival, one-year survival, and overall survival.   

About the Study

Each arm of the study will enroll up to 20 patients, with the possibility of enrolling an additional five patients each (for a ma
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Positive Clinical Study Results for BSPs HyperQ Technology
2. 15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
3. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
4. Marshall study shows nanoparticles used as additives in diesel fuels can travel from lungs to liver
5. Clionsky Neuro Systems (CNS-Neuro) Announces Publication of Study Finding Elderly Patients Unable to Recognize Their Memory Loss
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
8. Singapore scientists lead human embryonic stem cell study
9. GeneTex Antibody Company to Launch New Line of Primary Antibodies for the Study of Spindle Assembly
10. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
11. Metabolex Announces Positive Results From its Clinical Study of Arhalofenate in Combination With Febuxostat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , May 20, 2013  (PSHR) Pacific ... naturally based products across a broad range of ... has retained investor relations firm, BlueWater Advisory Group, ... return to trading process, and to direct the ... initiation. Matthew Mills ...
(Date:5/20/2013)... May 20, 2013 Cempra, Inc. (Nasdaq: ... differentiated antibiotics to meet critical medical needs in ... it presented data at the American Thoracic Society ... demonstrating the antibacterial and enhanced immunomodulatory ... Phase 2 clinical trial in outpatients with community ...
(Date:5/20/2013)... 2013 Recognizing exciting and innovative ... to its 2013 Class of Young Professors. ... provide this outstanding international group with more than ... science to meet global challenges.     , The DuPont ... young and untenured research faculty working in areas ...
(Date:5/19/2013)... NY (PRWEB) May 19, 2013 ... boat, today announced a new speed record for a ... from Las Palmas, Spain, on April 25, 2013, the ... Atlantic Ocean at the average speed of 5.3 knots ... Indies on May 18, 2013. The first-of-its-kind catamaran completed ...
Breaking Biology Technology:Pacific Shore Holdings Retains Investor Relations Firm 2Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) 2DuPont Celebrates Scientific Innovation by Recognizing Young Professors 2DuPont Celebrates Scientific Innovation by Recognizing Young Professors 3MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 2MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 3MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 4MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 5MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 6
... , New book by Advanced Cell Technology,s Chief Scientist, Robert ... WORCESTER, Mass., June 16 MSNBC.com featured today Dr. Robert ... How Life and Consciousness are the Keys to Understanding the ... award-winning site "Cosmic Log." The article by Science Editor ...
... , QUINCY, Mass., June 16 ... biotech developer and manufacturer of next-generation, renewable biochemicals ... LLC (Myriant) to incorporate all of its biobased ... continue its pursuit of biofuels opportunities, including its ...
... to present best practices for improving drug safety and reducing ... 16 Covance Inc. is pleased to announce the complete ... Drug Information Association,s (DIA) 45th Annual Meeting from ... , , The DIA Annual Meeting is the biopharmaceutical ...
Cached Biology Technology:MSNBC Publishes Free Online Abridgment of 'Biocentrism' 2MSNBC Publishes Free Online Abridgment of 'Biocentrism' 3BioEnergy International, LLC Announces Formation of Myriant Technologies LLC 2Covance to Present at the Drug Information Association's 45th Annual Meeting 2Covance to Present at the Drug Information Association's 45th Annual Meeting 3Covance to Present at the Drug Information Association's 45th Annual Meeting 4Covance to Present at the Drug Information Association's 45th Annual Meeting 5
(Date:5/16/2013)... a gene involved in neurodegenerative disease also plays a ... clock. , In a study of the common ... keeps the clock responsible for sleeping and waking on ... the fruit fly,s sleep-wake cycle is disturbed, making waking ... , The discovery is particularly interesting because mutations ...
(Date:5/16/2013)... endothelium, the cellular layer lining the body,s blood ... hundred nanometers in thickness, this super-tenuous structure routinely ... compression to create a unique and highly dynamic ... tissues from the body,s circulatory system. , It,s ... must be physically breached to enable immune ...
(Date:5/16/2013)... players and athletes choose to wear the color red ... in Psychological Science , a journal of the ... to do with their testosterone levels. , The new ... University of Sunderland and colleagues, demonstrated that males who ... had higher testosterone levels than other males who chose ...
Breaking Biology News(10 mins):Gene involved in neurodegeneration keeps clock running 2Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4High-testosterone competitors more likely to choose red 2
... at Carnegie Mellon University,s Robotics Institute have received a ... Department of Agriculture (USDA) to build automated farming systems. ... orange growers, but both are designed to improve fruit ... sensors on autonomous robotic vehicles or at fixed sites ...
... Central Florida professor show early promise for destroying breast ... the formation and spread of breast cancer tumors in ... break up a cancer-causing protein called STAT3, and researchers ... "The compounds are very promising," Turkson said. "They,ve worked ...
... 30 Orchid Cellmark Inc.,(Nasdaq: ORCH ), a leading ... for the third quarter of 2008. , ... of 2008 compared,to $15.6 million for the third quarter of 2007. ... compared to a year ago was largely due,to lower revenues in ...
Cached Biology News:Carnegie Mellon developing automated systems to enable precision farming of apples, oranges 2Carnegie Mellon developing automated systems to enable precision farming of apples, oranges 32 new compounds show promise for eliminating breast cancer tumors 2Orchid Cellmark Reports Third Quarter 2008 Financial Results 2Orchid Cellmark Reports Third Quarter 2008 Financial Results 3Orchid Cellmark Reports Third Quarter 2008 Financial Results 4Orchid Cellmark Reports Third Quarter 2008 Financial Results 5Orchid Cellmark Reports Third Quarter 2008 Financial Results 6Orchid Cellmark Reports Third Quarter 2008 Financial Results 7Orchid Cellmark Reports Third Quarter 2008 Financial Results 8